Rare Disease Treatment Company CEO Sells All Shares Immediately After Exercising Stock Options

On the 1st, Eric M. Dube, CEO of Travere Therapeutics, Inc. (NASDAQ: TVTX)—a Nasdaq-listed developer of rare disease therapies—exercised all 60,000 of his employee stock options at $15.46 per share and immediately sold them in the open market.

He executed two sell orders at approximately $30.55 and $31.46 per share, respectively, realizing total proceeds of about $1.84 million (roughly ₩2.5 billion). After these transactions, Dube directly holds approximately 432,886 shares.

The options, granted on January 31, 2020, were fully vested at the time of exercise. Compared with his position immediately before exercising, his net ownership stake declined only marginally.

On February 19, the company reported its Q4 and full-year 2025 results along with its 2026 business outlook, highlighting strong sales growth of its IgA nephropathy treatment, FILSPARI. At the same time, the FDA extended its review of the supplemental application for the FSGS indication, resetting the PDUFA target action date to April 13.

Following related disclosures, several law firms have launched investigations into potential securities-law violations. Meanwhile, JP Morgan and Piper Sandler have raised their price targets for Travere Therapeutics, citing the strength of the FILSPARI pipeline and the company’s growth prospects.

Travere Therapeutics is a U.S. biotech company focused on developing and commercializing therapies for rare diseases, including rare kidney disorders. Its oral drug FILSPARI is being positioned for both IgA nephropathy and FSGS markets.

Eric Dube, who has led the company since 2019 as a rare-disease industry executive, continues to maintain a substantial equity stake even after this transaction, according to regulatory filings.